Epiomic Epidemiology Series: Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027

Wednesday, July 19, 2017 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 18, 2017 /PRNewswire/ -- Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Type 1 Diabetes Mellitus in 12 Major Markets

Type 1 Diabetes Mellitus (T1DM) is a multisystem disease that progressively destroys the pancreas' ability to produce insulin. This leads to a chronic condition of defective metabolism of fat, carbohydrates and proteins due to the lack of insulin.
It occurs mainly in childhood and adolescents, however a rising number of latent autoimmune diabetes of adulthood (LADA) cases have been reported mainly due to a better understanding and diagnosis of the disease. Read the full report: http://www.reportlinker.com/p04825421/Epiomic-Epidemiology-Series-Type-1-Diabetes-Mellitus-Forecast-in-12-Major-Markets.htmlThis report provides the current prevalent population for Type 1 Diabetes Mellitus across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China and Russia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Type 1 Diabetes Mellitus have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. There are many co-morbidities associated with Type 1 Diabetes Mellitus, including: • Chronic pancreatitis • Cystic fibrosis • Autoimmune disorders • Hyperglycaemia • Heart and blood vessel diseases (MI, Stroke, Atherosclerosis, Hypertension, Angina) • Neuropathy • Nephropathy (leading to CKD) • Ulcerations • Eye damage (retinopathy) • Foot damage • Ketoacidosis • Lower limb amputation • Skin/Mouth conditions • Pregnancy complications This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report. Reason to buy • Able to quantify patient populations in global Type 1 Diabetes Mellitus market to target the development of future products, pricing strategies and launch plans. • Gain further insight into the prevalence of the subdivided types of Type 1 Diabetes Mellitus and identify patient segments with high potential. • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries. • Provide a level of understanding on the impact from specific co-morbid conditions on Type 1 Diabetes Mellitus prevalent population. • Identify sub-populations within Type 1 Diabetes Mellitus which require treatment. • Gain an understanding of the specific markets that have the largest number of Type 1 Diabetes Mellitus patients.

Read the full report: http://www.reportlinker.com/p04825421/Epiomic-Epidemiology-Series-Type-1-Diabetes-Mellitus-Forecast-in-12-Major-Markets.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com __________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/epiomic-epidemiology-series-type-1-diabetes-mellitus-forecast-in-12-major-markets-2017-2027-300490289.html

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store